Indonesia court finds drugmakers at fault over toxic cough syrup, awards parents
Adds comment from family lawyer in paragraph 9-10
By Stanley Widianto
JAKARTA, Aug 23 (Reuters) -An Indonesian court ordered two local companies to pay up to 60 million rupiah ($3,850) to each family whose children died of an acute kidney injury or were seriously injured after consuming toxic cough syrup.
More than 200 children in Indonesia died of the injury and about 120 more survived, some of whom lived with disabilities which led to financial hardships for their parents.
Indonesian courts have cited lax oversight by pharmaceutical companies, including local drugmakers and some suppliers, as well as the country's food and drugs agency (BPOM), in hearings into the poisonings.
In late 2022, more than 20 families launched a civil suit against the agency, the health ministry, and several companies.
Judges at the Central Jakarta court found a drugmaker and a supplier, Afi Farma and CV Samudera Chemical, at fault in the poisonings, according to a ruling released late on Thursday.
The health ministry and the BPOM were cleared of wrongdoing.
The court ordered the companies to pay the parents who brought the suit compensation of 50 million rupiah for children who died and 60 million rupiah for children who were injured.
Parents had asked for 3.4 billion rupiah for each child that died, and 2.2 billion rupiah for survivors. Indonesia's 2023 gross domestic product per capita was nearly $5,000, data from the country's Statistics Bureau shows.
Siti Habiba, the lawyer for the parents, said the families were disappointed by the ruling, as the money was given "as though we were beggars."
"This breaks a lot of the victims' hearts," she said, adding the court ignored the parents' government oversight concerns by not finding the health ministry and the BPOM at fault.
The court document, posted on its website, did not include reasons for the decision.
Afi Farma's lawyer Reza Wendra Prayogo told Reuters on Friday the firm was "disappointed" with the civil case ruling and the company was still considering its next legal step.
Last year, a criminal court found East Java-based drugmaker Afi Farma guilty of negligence and jailed officials for not testing the ingredients sent by its supplier.
The syrups contained ethylene glycol (EG), a commonly used chemical in products such as brake fluid and antifreeze. A court document from that criminal case said the EG concentration in the syrups reached as high as 99%, where international standards say only 0.1% of EG is safe for consumption.
The company has repeatedly denied negligence.
Reuters could not immediately contact CV Samudera Chemical, an Indonesian soapmaker, whose toxic ingredient made its way to Afi Farma, according to the court document of the Afi Farma criminal case in 2023.
The World Health Organization said the contaminated medicines had also killed children in Gambia and Uzbekistan in 2022.
($1 = 15,595 rupiah)
Reporting by Stanley Widianto; Editing by Michael Perry and Stephen Coates
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.